Caroline serves as SVP, asset and portfolio leadership, for Mariana Oncology. She brings 15-plus years of experience in oncology drug development, with a proven track record of preclinical, translational, and clinical development, from candidate nomination through approval. Before joining Mariana Oncology, Caroline was SVP, global disease area lead, at SpringWorks Therapeutics (NASDAQ: SWTX), where she worked on OGSIVEO™, a targeted therapy recently approved for the treatment of desmoid tumors and in development for multiple myeloma and ovarian granulosa cell tumors.

She previously served as VP, R&D programs and strategy, at Turnstone Biologics (NASDAQ: TSBX), having joined as the first full-time employee, where she was responsible for cross-functional leadership of oncolytic immunotherapy and autologous cell therapy programs. Prior to Turnstone, Caroline was VP, clinical & translational research, at SillaJen Biotherapeutics (formerly Jennerex Biotherapeutics), where she designed and executed preclinical and clinical studies to elucidate mechanism of action of oncolytic immunotherapies, leading to publications in Nature, Nature Medicine, and Science Translational Medicine.

Caroline received her PhD in biochemistry, microbiology, and immunology from the University of Ottawa, and an honors degree from McGill University.